XIAP and acute lymphoblastic leukemia: Phase II clinical trials testing the efficacy of the XIAP-antagonists have been set up in the case of LCL-161 for the treatment of triple negative breast cancer and forms of myelofibrosis as well as for TL32711 for the treatment of patients with acute myelogenous leukemia and ALL (ClinicalTrials.gov).